Humans and AI will soon crack de novo antibody design

Our Observations

1. AI companies either scale with compute or don't scale at all
2. Proteins are dynamic structures, but existing data is biased toward static structures
3. ML objectives must explicitly optimize diversity else models fail to generalize outside the narrow slice of measured antibody space

Partnership

We are currently developing AI-designed VHH antibody libraries for CRO partners to enhance hit discovery and maturation for difficult targets. Email us - [email protected].